Last $2.47 USD
Change Today 0.00 / 0.00%
Volume 0.0
OXGN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

oxigene inc (OXGN) Snapshot

Open
$2.49
Previous Close
$2.47
Day High
$2.54
Day Low
$2.40
52 Week High
03/12/14 - $5.40
52 Week Low
02/12/14 - $1.96
Market Cap
51.1M
Average Volume 10 Days
380.6K
EPS TTM
$-3.41
Shares Outstanding
20.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXIGENE INC (OXGN)

oxigene inc (OXGN) Related Bloomberg News

View More Bloomberg News

oxigene inc (OXGN) Related Businessweek News

No Related Businessweek News Found

oxigene inc (OXGN) Details

OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops therapeutics primarily to treat cancer. The company focuses on developing vascular disrupting agents (VDAs) that disrupt abnormal blood vessels associated with solid tumor progression. Its principal clinical product candidate is ZYBRESTAT, which is in development as a treatment for solid tumors. The company is also developing OXi4503, a second-generation product candidate for acute myeloid leukemia. OXiGENE, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

9 Employees
Last Reported Date: 03/20/14
Founded in 1988

oxigene inc (OXGN) Top Compensated Officers

Chief Financial Officer and Principal Account...
Total Annual Compensation: $241.3K
Compensation as of Fiscal Year 2013.

oxigene inc (OXGN) Key Developments

OXiGENE, Inc. Announces Management Changes

OXiGENE, Inc. announced that David (Dai) Chaplin, Ph.D., has been appointed to the position of President and Chief Executive Officer, replacing Peter Langecker, M.D., Ph.D. Dr. Chaplin is current member of OXiGENE's Board of Directors. Prior to joining OXiGENE in 2000 as Chief Scientific Officer, Dr. Chaplin served as Vice President of Oncology for Aventis, where he was in charge of all oncology drug discovery and early clinical development worldwide.

OXiGENE, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014

OXiGENE, Inc. reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported loss from operations of $2,628,000 against $1,881,000 for the same period in the last year. Net loss and comprehensive loss was $2,630,000 against $1,880,000 for the same period in the last year. Basic and diluted net loss per share attributable to common stock was $0.29 against $0.97 for the same period in the last year. The increase in the net loss in 2014 as compared to 2013 was primarily related to an increase in research and development (R&D) expenses of $0.6 million.

OXiGENE, Inc., Annual General Meeting, Jun 10, 2014

OXiGENE, Inc., Annual General Meeting, Jun 10, 2014., at 10:00 Pacific Standard Time. Location: 701 Gateway Boulevard, Suite 210. Agenda: To elect six members to the board of directors to hold office until the 2015 annual meeting of stockholders and until their successors are duly elected and qualified; to ratify the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2014; and to transact such other business as may be properly brought before the annual meeting and any adjournments thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXGN:US $2.47 USD 0.00

OXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXGN.
View Industry Companies
 

Industry Analysis

OXGN

Industry Average

Valuation OXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 237.3x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 282.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXIGENE INC, please visit www.oxigene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.